FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506899031> ?p ?o ?g. }

• W2506899031 abstract "Abstract Introduction. Investigators from Johns Hopkins University pioneered the use of post-transplantation cyclophosphamide (PT-Cy) after T cell-replete haploidentical bone marrow (BM) infusion. A significant component of this scheme is tacrolimus (FK), associated to mycophenolate mofetil (MMF), to prevent immunological complications. FK is a calcineurin inhibitor, almost 100-fold more potent than cyclosporine A (CyA) in its inhibitory activity. In this retrospective study, we analyzed 100 patients grafted with Haplo-SCT with PT-Cy, and receiving FK or CyA. Patients and Methods. From April 2009 until April 2013, we analyzed 100 consecutive patients at two institutions (Institut Paoli Calmettes Marseille, France and Humanitas Cancer Center, Rozzano, Italy). Conditioning regimen was identical consisting of Fludarabine, Cyclophosphamide, and low dose TBI. GVHD prophylaxis consisted of Cy 50 mg/kg on days +3 and +4, FK or CyA and MMF. FK (at a total dose of 1 mg) was administered as a continuous infusion and then converted to oral formulation. CyA was dosed at 3 mg/kg as a continuous infusion and was then converted to oral formulation. MMF was administered at 45 mg/kg/day until day +35. FK, CyA and MMF were started on day +5. FK and CyA were tapered by day +100-180. Stem cell source was BM or peripheral blood stem cells (PBSC). Results. Patient and transplant characteristics are shown in Table 1. The cumulative incidence of engraftment was similar between FK and CyA groups: 30-days absolute neutrophil count > 500 was 79% vs 91% (p 0.3), and unsupported platelet count more than 20 000 at 60 days was 77% vs 84% (p 0.7), respectively. The incidence of grade 2-4 acute GVHD was 26% vs 30% (p 0.5) and the incidence of chronic GVHD was 13% vs 8% (p 0.9), respectively. The 2-year progression free survival (PFS) and overall survival (OS) were 53% vs 64% (p 0.2) and 65% vs 65%, respectively (p 0.7). The 2-year relapse incidence (RI) was 28% vs 12% (p 0.08) and the 2-year non relapse mortality was 16% vs 14% (p 0.7), respectively. In univariate analysis, only disease status (CR vs not CR) impacted the PFS, OS, and RI. Patients were regrouped in 3 cohorts (1 patient excluded because received FK + PBSC): FK + BM (n 42), CyA + BM (n 14), and CyA + PBSC (n 43). 1-year NRM was not different (17% vs 14% vs 15%, p 0.8). Compared to FK +BM and CyA + PBSC, a trend in favor of CyA + BM was observed in terms of aGVHD (7% vs 24% vs 38%, p 0.05) and cGVHD (0 vs 13% vs 10%, p 0.9). Conclusions. Although this is a retrospective study with potential selection bias, using CyA instead of standard FK did not seem to affect any major clinical outcome, with special interest for aGVHD and cGVHD. The NRM is acceptable in line with that published. GVHD incidence was lower in the group CyA + BM compared to other 2 groups. Disease status before haplo SCT was the only prognostic factor for survival and relapse. Table 1. Patient and transplant characteristics. All pts FK CSA p N % N % 100 43 57 Male Female 58/42 22/21 51/49 36/21 63/37 0.229 Age (mean) 46 44 48 0.135 Disease status at haplo 0.466 CR 56 23 53 33 58 PR 29 14 33 15 26 SD 6 1 2 5 9 PD 9 5 12 4 7 Armand Risk 0.646 Low 9 3 7 6 11 Int 72 33 77 39 68 High/Very high 19 7 16 12 21 Previous transplant <0.001 Relapse after ALLO 8 0 0 8 14 Relapse after HDC 40 21 49 19 33 Sex D/R 0.533 F/F 16 9 21 7 12 F/M 21 8 19 13 23 M/M 38 14 33 24 42 M/F 25 12 28 13 23 CMV D/R 0.009 POS/POS 70 35 81 35 61 NEG/NEG 18 2 5 16 28 POS/NEG 11 6 14 5 9 Donor 0.578 children 26 12 28 14 25 Mother 15 7 16 8 14 Father 11 6 14 5 9 Sibling 47 17 40 30 53 Cousin 1 Stem cell source <0.001 BM 56 42 98 14 25 PBSC 44 1 2 43 75 HCT-CI 0.007 0 31 18 42 13 23 1-2 23 13 30 10 18 >3 46 12 28 34 60 CD34 (mean) 4,4 3,5 5,2 <0.001 Disclosures No relevant conflicts of interest to declare." @default.
• W2506899031 created "2016-08-23" @default.
• W2506899031 creator A5000359788 @default.
• W2506899031 creator A5010613445 @default.
• W2506899031 creator A5015429867 @default.
• W2506899031 creator A5021060422 @default.
• W2506899031 creator A5022161221 @default.
• W2506899031 creator A5029271233 @default.
• W2506899031 creator A5042459008 @default.
• W2506899031 creator A5045261121 @default.
• W2506899031 creator A5045967298 @default.
• W2506899031 creator A5048023278 @default.
• W2506899031 creator A5048650165 @default.
• W2506899031 creator A5058760899 @default.
• W2506899031 creator A5059804319 @default.
• W2506899031 creator A5061282516 @default.
• W2506899031 creator A5079071242 @default.
• W2506899031 creator A5082045927 @default.
• W2506899031 creator A5082515771 @default.
• W2506899031 date "2014-12-06" @default.
• W2506899031 modified "2023-09-27" @default.
• W2506899031 title "Tacrolimus (FK) Compared to Cyclosporine a (CyA) after Haploidentical T Cell Replete Stem Cell Transplantation (Haplo-SCT) with Post-Infusion Cyclophosphamide: A Retrospective Analysis" @default.
• W2506899031 doi "https://doi.org/10.1182/blood.v124.21.3902.3902" @default.
• W2506899031 hasPublicationYear "2014" @default.
• W2506899031 type Work @default.
• W2506899031 sameAs 2506899031 @default.
• W2506899031 citedByCount "0" @default.
• W2506899031 crossrefType "journal-article" @default.
• W2506899031 hasAuthorship W2506899031A5000359788 @default.
• W2506899031 hasAuthorship W2506899031A5010613445 @default.
• W2506899031 hasAuthorship W2506899031A5015429867 @default.
• W2506899031 hasAuthorship W2506899031A5021060422 @default.
• W2506899031 hasAuthorship W2506899031A5022161221 @default.
• W2506899031 hasAuthorship W2506899031A5029271233 @default.
• W2506899031 hasAuthorship W2506899031A5042459008 @default.
• W2506899031 hasAuthorship W2506899031A5045261121 @default.
• W2506899031 hasAuthorship W2506899031A5045967298 @default.
• W2506899031 hasAuthorship W2506899031A5048023278 @default.
• W2506899031 hasAuthorship W2506899031A5048650165 @default.
• W2506899031 hasAuthorship W2506899031A5058760899 @default.
• W2506899031 hasAuthorship W2506899031A5059804319 @default.
• W2506899031 hasAuthorship W2506899031A5061282516 @default.
• W2506899031 hasAuthorship W2506899031A5079071242 @default.
• W2506899031 hasAuthorship W2506899031A5082045927 @default.
• W2506899031 hasAuthorship W2506899031A5082515771 @default.
• W2506899031 hasConcept C126322002 @default.
• W2506899031 hasConcept C2776694085 @default.
• W2506899031 hasConcept C2776755627 @default.
• W2506899031 hasConcept C28328180 @default.
• W2506899031 hasConcept C2909675724 @default.
• W2506899031 hasConcept C2911091166 @default.
• W2506899031 hasConcept C54355233 @default.
• W2506899031 hasConcept C71924100 @default.
• W2506899031 hasConcept C86803240 @default.
• W2506899031 hasConceptScore W2506899031C126322002 @default.
• W2506899031 hasConceptScore W2506899031C2776694085 @default.
• W2506899031 hasConceptScore W2506899031C2776755627 @default.
• W2506899031 hasConceptScore W2506899031C28328180 @default.
• W2506899031 hasConceptScore W2506899031C2909675724 @default.
• W2506899031 hasConceptScore W2506899031C2911091166 @default.
• W2506899031 hasConceptScore W2506899031C54355233 @default.
• W2506899031 hasConceptScore W2506899031C71924100 @default.
• W2506899031 hasConceptScore W2506899031C86803240 @default.
• W2506899031 hasLocation W25068990311 @default.
• W2506899031 hasOpenAccess W2506899031 @default.
• W2506899031 hasPrimaryLocation W25068990311 @default.
• W2506899031 hasRelatedWork W2471320594 @default.
• W2506899031 hasRelatedWork W2494119277 @default.
• W2506899031 hasRelatedWork W2554858294 @default.
• W2506899031 hasRelatedWork W2562534490 @default.
• W2506899031 hasRelatedWork W2573761336 @default.
• W2506899031 hasRelatedWork W2586355990 @default.
• W2506899031 hasRelatedWork W2589310070 @default.
• W2506899031 hasRelatedWork W2592131559 @default.
• W2506899031 hasRelatedWork W2912454193 @default.
• W2506899031 hasRelatedWork W2912805204 @default.
• W2506899031 hasRelatedWork W2912903223 @default.
• W2506899031 hasRelatedWork W2914917272 @default.
• W2506899031 hasRelatedWork W2972799950 @default.
• W2506899031 hasRelatedWork W2977871361 @default.
• W2506899031 hasRelatedWork W2979803117 @default.
• W2506899031 hasRelatedWork W2979848766 @default.
• W2506899031 hasRelatedWork W2992468690 @default.
• W2506899031 hasRelatedWork W3000052376 @default.
• W2506899031 hasRelatedWork W3139359447 @default.
• W2506899031 hasRelatedWork W3173633718 @default.
• W2506899031 isParatext "false" @default.
• W2506899031 isRetracted "false" @default.
• W2506899031 magId "2506899031" @default.
• W2506899031 workType "article" @default.